US · Healthcare · Biotechnology
EPS came in at -0.37 against a street estimate of -0.31 — a miss of 19.4%.
Analysts rate Tango Therapeutics Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $47.09.
| Fund | Stake |
|---|---|
| RTW INVESTMENTS, LLC | 8.24% |
| BlackRock Inc | 7.38% |
| FMR Inc | 7.31% |
| Farallon Capital Management, L.L.C. | 7.28% |
| Boxer Capital Management, LLC | 6.45% |
| The Goldman Sachs Group Inc | 5.92% |
| TCG Crossover Management, LLC | 5.39% |
| TRV GP IV, LLC | 3.78% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Tango Therapeutics reported updated Phase 1/2 results for vopimetostat combined with RAS(ON) inhibitors in MTAP-deleted, RAS-mutan | 2026-10-23 |
| Quarterly report · Q2 2026 TANGO THERAPEUTICS, INC. – Q2 2026 SUMMARY HEADLINE NUMBERS • Cash and Marketable Securities: $1,013,990 thousand ($345,558k cash + $668,432k securi | 2026-08-11 |
| Company announcement · Q3 2026 TANGO THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company filed an updated at-the-market (ATM) offering program on August 11, 2026 for up to | 2026-08-11 |
| Results announced · Q3 2026 TANGO THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $1.0 billion as of June 30, 2026 (comprised of $345.6 million | 2026-08-11 |
| Board / officer change · Q3 2026 TANGO THERAPEUTICS, INC. (TNGX) – 8-K SUMMARY HEADLINE NUMBERS • Executive Chair Departure: Dr. Barbara Weber's employment ended August 3, 2026 • No | 2026-08-06 |
| Board / officer change · Q2 2026 TANGO THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 6 to 7 directors on June 19, 2026 • New director Robert Azelby r | 2026-06-23 |
| Quarterly report · Q1 2026 TANGO THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $379.8 million as of March 31, 2026 (up from $343.1 | 2026-05-13 |
| Proxy statement · Q2 2026 TANGO THERAPEUTICS, INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class II Directors – Malte Pe | 2026-04-17 |
Readable in the app.
| Announcement | Date |
|---|---|
| New clinical supply agreement with Erasca for RAS inhibitor combination studies Tango Therapeutics, a clinical-stage biotech company, reported strong progress on its lead cancer drug vopimetostat in early 2026. Key highlights: The company has $343 million in cash provid | 2026-03-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tango Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.